MedX Health Corp
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MedX Health Corp (TSXV:MDX, OTCQB:MDXHF) develops, manufactures and markets medical devices and software focused on teledermatology skin cancer screening and photobiomodulation therapy for pain relief and tissue repair. Founded in 1999 and headquartered in Mississauga, Ontario, Canada, the company operates primarily in Canada, the United States and Europe, with expanding distribution in the United Kingdom, Italy, Turkey, United Arab Emirates and other international markets. Its core products include the DermSecure teledermatology platform featuring SIAscopy technology for non-invasive multispectral imaging of skin lesions to detect suspicious moles and melanoma; MoleMate and SIMSYS diagnostic systems providing five-sectional analysis of chromophores such as collagen, blood and melanin; and MedX Laser Therapy devices, which are FDA-approved Class III cold lasers and LEDs delivering low-level light energy for rehabilitation, wound healing and pain management; all supported by HL7 FHIR-enabled electronic health records interoperable across 38 territories. In recent developments, MedX launched DermSecure screening services in Newfoundland and Labrador and with Medicure Clinic in 2025, added three new Ontario locations, appointed Tarek El Hoss as Senior Vice President of Market Development and Sales and Naman Demaghlatrous to its board in mid-2025, and signed commercial distribution agreements with Vitamed Biomedical for Italy, Makromed/Arhan Global A.Ş. for Turkey and Health Partners following a successful UK pilot; the company also closed a non-brokered private placement raising approximately CAD 2 million in November 2025 and announced a proposed placement for up to CAD 2.5 million in July 2025 to support expansion.
MedX Announces Final Closing of Non-brokered Private Placement
MedX Announces Application for Final Extension of Non-Brokered Private Placement
MedX Announces Application for Extension of Non-Brokered Private Placement
MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes
MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes
MedX Health 2025 YEAR REVIEW
MedX Announces Final Closing of Non-Brokered Private Placement
MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement
MedX Health Appoints Dr. Symon Cotton as Strategic Advisor on AI & Product Development
MedX Health Appoints Global Skin Science Leader Dr. Paul Matts as Strategic Advisor
MedX Announces Proposed Extension of Non-Brokered Private Placement
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MedX Announces Proposed Non-Brokered Private Placement to Raise up to $2,500,000 and Stock Option Grants
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MedX Announces the Engagement of Market Maker Consultant
MedX Announces Final Closing of Non-Brokered Private Placement
MedX Health, Vitamed Biomedical, and Medispa Partner to Expand Teledermatology Services Across Italy
MDXH Stock: 38.06% Fall Explained
MedX Health says its SIAscopy/DermSecure products show significant promise as it reports Q1 results
MedX Health says revenue in 2021 rose from previous year despite tough conditions